Bio-Rad Laboratories (BIO) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue was $651 million, flat year-over-year as reported and down 1.9% currency-neutral, with Clinical Diagnostics growth offset by Life Science softness; digital PCR instrument revenue grew over 20%.

• Net income for Q2 2026 was $371.4 million, up from $317.8 million in Q2 2025, driven by gains in equity securities, notably Sartorius AG; non-GAAP net income was $70.2 million, nearly flat year-over-year.

• Organizational restructuring was announced, targeting $30–$35 million net annualized savings by end of 2027, with estimated pre-tax charges of $80–$90 million and minimal 2026 impact.

• Operating cash flow reached $99 million, and $32 million of shares were repurchased during the quarter; cash and short-term investments totaled $1.62 billion as of June 30, 2026.

• The company reaffirmed its full-year Non-GAAP guidance, expecting flat to slightly negative revenue growth and stable margins.

Financial highlights

• Life Science segment Q2 revenue was $252 million, down 4.1% year-over-year (down 5.1% currency-neutral), mainly due to academic research market challenges.

• Clinical Diagnostics segment Q2 revenue was $399 million, up 2.6% year-over-year (up 0.3% currency-neutral), led by quality systems, diabetes, and blood typing products.

• Consolidated gross margin was 53.1% (GAAP) and 53.9% (Non-GAAP), both slightly up year-over-year and sequentially.

• Q2 Non-GAAP net income was $70.2 million ($2.62 EPS), nearly flat versus $71 million ($2.61 EPS) in Q2 2025.

• Operating income was $72.6 million (GAAP), down from $77.1 million last year; Non-GAAP operating margin was 12.5%, up from 6.6% in Q1 but down from 13.6% last year.

Outlook and guidance

• Full-year 2026 Non-GAAP currency-neutral revenue growth expected between -3% and +0.5%.

• Life Science segment guidance: -3% to -1% currency-neutral growth; Clinical Diagnostics: -3% to +1%.

• Q3 revenue expected to be flat sequentially, with a mid-single-digit ramp in Q4.

• Full-year Non-GAAP gross margin expected between 53% and 54%; operating margin between 10% and 12%.

• Free cash flow estimate reaffirmed at $290 million–$340 million.